Pap smear screening for cervical cancer in Singapore: Issues to consider

Singapore Medical Journal

Volumn 45, Issue 6, 2004, Pages 244-246

  Tay, Eng Hseon ^a  

^a KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

ACCREDITATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CARCINOGENESIS; CLINICAL LABORATORY; COMPUTER ASSISTED DIAGNOSIS; EDITORIAL; HUMAN; PAPANICOLAOU TEST; QUALITY CONTROL; SEROCONVERSION; SINGAPORE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS INFECTION; WART VIRUS;

FEMALE; HUMANS; MASS SCREENING; SINGAPORE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 3042582225     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (17)

1. Chia KS, Seow A, Lee HP, Shanmugaratnam K. Trends in Cancer Incidence in Singapore 1993-1997. Singapore Cancer Registry Report No. 5.
2. Anttila A, Pukkala E, Soderman B, Kallio M, Nieminen P, Hakama M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer 1999; 83:59-65.
3. Wain G, Hacker NF. Pitfalls in the screening and early diagnosis of cervical cancer. Curr Opin Obstet Gynecol 1990; 2:74-9.
4. Mubiayi N, Bogaert E, Boman F, Leblanc E, Vinatier D, Leroy JL, Querleu D. Cytological history of 148 women presenting with invasive cervical cancer. Gynecol Obstet Fertil 2002; 30:210-7.
5. Special issue [Topics on quality assurance in cervical cytology]. Acta Cytol 1996; 40:1-142.
6. Coppleson M, Reid BL, Skladnev VN, Dalrymple JC. An electronic approach to the detection of pre-cancer and cancer of the uterine cervix: a preliminary evaluation of Polarprobe. Int J Gynecol Cancer 1994; 4:79-83.
7. Broadstock M. Effectiveness and cost effectiveness of automated and semi-automated cervical screening devices: a systematic review of the literature. N Z Med J 2001; 114:311-3.
8. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995; 87:796-802.
9. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papilloma virus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9.
10. Cox JT. Clinical role of HPV testing. Obstet Gynecol Clin North Am 1996; 23:811-51.
11. ASCUS-LSIL Traige Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188:1383-92.
12. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papilloma virus type 16 vaccine. N Engl J Med 2002; 347:1645-51.
13. Davey DD. Papanicolaou smear 5-year retrospective review: what is required by the Clinical Laboratory Improvement Amendments of 1988? Arch Pathol Lab Med 1997; 121:296-8.
14. Jones BA. Rescreening in gynecologic cytology. Rescreening of 8096 previous cases for current low-grade and indeterminate-grade squamous intraepithelial lesion diagnoses - a College of American Pathologists Q-Probes study of 323 laboratories. Arch Pathol Lab Med 1996; 120:519-22.
15. Wilbur DC. False negatives in focused rescreening of Papanicolaou smears: how frequently are "abnormal" cells detected in retrospective review of smears preceding cancer or high-grade intraepithelial neoplasia? Arch Pathol Lab Med 1997; 121:273-6.
16. Chang AR. The pivotal role of the pathology laboratory in the context of a Singapore cervical cancer screening programme. Singapore Med J 2004; 45:257-66.
17. Haeney MR, Blair C. Raising standards in pathology: the accreditation process in the United Kingdom. J Qual Clin Pract 1998; 18:75-82.